Amgen Inc.

Amgen Inc.

AMGNNYSE / NASDAQHealthcareLarge cap

$435.64-$3.18 (-0.7%)

Last close · Data as of Nov 20, 2026

Market cap
$186.5B
P/E
24.2x
EV / EBITDA
13.7x
Revenue
$36.8B
Net margin
21.0%
ROCE
13.9%

+29.6% over the last year

Amgen Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.8%
3M
+0.4%
6M
+31.4%
1Y
+29.6%
5Y
+111.4%

52-week range

Day change -$3.18 (-0.7%) from $439 to $436 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AMGN, bought on each weekday since 2021.

News & filings

What Amgen filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 24.7% against a peer median of 22.2%.

Concerns

No concern stands out for this company on the data on file.

  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Read moreShow less

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Sector
Healthcare
Shares outstanding
538.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$186.5B
P/E
24.2x
P/B
21.5x
EV / EBITDA
13.7x
EV / Sales
6.3x
P/S
5.1x
52-week high
$478.48
52-week low
$313.85

Profitability

Operating margin
24.7%
Net margin
21.0%
EBITDA margin
46.0%
ROE
89.1%
ROCE
13.9%
ROA
8.5%
Asset turnover
0.41

Growth

Revenue
$36.8B
Revenue growth, 1Y
10.0%
Revenue CAGR, 3Y
11.8%
Net profit growth, 1Y
88.5%
Free cash flow
$8.1B

Solvency

Current ratio
1.14
Debt / Equity
6.31
Debt / Assets
0.60
CFO / Net profit
1.29
Cash / Market cap
4.9%

Where the revenue went

Of every $100 of FY2025 revenue, $21 was left as net income.

Amgen Inc. income statement flow, FY2025
Amgen Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$12.0B
RevenueGross profit$24.7B
Gross profitResearch and development$7.3B
Gross profitSelling, general and administrative$7.0B
Gross profitOther operating expenses$1.3B
Gross profitOperating income$9.1B
Operating incomePretax income$9.0B
Operating incomeInterest and other expense$104.0M
Pretax incomeTax and other$1.3B
Pretax incomeNet income$7.7B

Revenue and net profit

Revenue grew 10.0% in FY2025; net profit is the dashed line.

Amgen Inc. revenue and net profit by fiscal year
Amgen Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$26.3B$6.6B
FY2023$28.2B$6.7B
FY2024$33.4B$4.1B
FY2025$36.8B$7.7B

Cash flows

FY2025: $10.0B from operations, $8.1B free after investment (dashed).

Amgen Inc. operating and free cash flow by fiscal year
Amgen Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$9.7B$8.8B
FY2023$8.5B$7.4B
FY2024$11.5B$10.4B
FY2025$10.0B$8.1B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$36.8B+10.0%1Y
EBITDA
$16.9B+26.5%1Y
Net profit
$7.7B+88.5%1Y
Cash from operations
$10.0B-13.3%1Y
Free cash flow
$8.1B-22.1%1Y
Revenue CAGR, 3Y
11.8%
Net profit CAGR, 3Y
5.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$36.8B$16.9B$7.7B$8.1B89.1%+10.0%+88.5%

Monthly returns

Month-by-month returns of AMGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$90.6B
Liabilities$81.9B
Equity$8.7B
Retained earnings-$25.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AMGN highlighted.

P/E against peers

AMGN trades at 24.2x earnings against a peer median of 25.5x.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Amgen Inc.AMGNthis company$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Peer median—25.5x3.2x12.5%15.8x

Year-to-date ROI

AMGN since 1 January, against earlier years.

Historical volatility

AMGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Amgen Inc. operating margin by fiscal year
Amgen Inc. operating margin by fiscal year
DateOperating margin
FY202236.3%
FY202328.0%
FY202421.7%
FY202524.7%
LineFY2025
Cost of revenueCost Of Revenue$12.0B
Gross profitGross Profit$24.7B
Operating expensesOperating Expense$15.6B
Research and developmentResearch And Development$7.3B
Selling, general and administrativeSelling General And Administration$7.0B
Other operating expensesOther Operating Expenses$1.3B
Total expensesTotal Expenses$27.7B
Pretax incomePretax Income$9.0B

Learn while you research

Academy chapters picked for Amgen Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 6.31 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →